In conclusion, our results suggest that SH-HCC is a distinctive variant of HCC, which develops more frequently in metabolic syndrome patients, and that senescent and damaged CAFs, as well as non-tumoral stellate cells with SASP, including IL-6 expression, may contribute to the development of SH-HCC. Here, IL6 is linked to hepatocellular carcinoma.